688506 百利天恒
已收盘 03-27 15:00:00
资讯
新帖
简况
百利天恒（688506）披露归还临时补充流动资金的募集资金公告，3月26日股价下跌3.09%
证券之星 · 03-26 22:12
百利天恒（688506）披露归还临时补充流动资金的募集资金公告，3月26日股价下跌3.09%
百利天恒（688506）1187.38万股限售股将于3月25日解禁，占总股本2.88%
证券之星 · 03-25 08:15
百利天恒（688506）1187.38万股限售股将于3月25日解禁，占总股本2.88%
百利天恒（688506）披露BL-ARC002获晚期实体瘤临床试验批准通知书，3月23日股价下跌4.89%
证券之星 · 03-23
百利天恒（688506）披露BL-ARC002获晚期实体瘤临床试验批准通知书，3月23日股价下跌4.89%
百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准
智通财经 · 03-22
百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准
每周股票复盘：百利天恒（688506）2.88%限售股将上市
证券之星 · 03-22
每周股票复盘：百利天恒（688506）2.88%限售股将上市
百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据
证券日报 · 03-19
百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据
百利天恒：1190万股限售股解禁 3月25日起上市流通
美股速递 · 03-17
百利天恒：1190万股限售股解禁 3月25日起上市流通
百利天恒：1187.38万股限售股3月25日解禁
南方财经网 · 03-17
百利天恒：1187.38万股限售股3月25日解禁
每周股票复盘：百利天恒（688506）完成1.99亿元股份回购
证券之星 · 03-15
每周股票复盘：百利天恒（688506）完成1.99亿元股份回购
百利天恒回购70万股 金额2亿元
财中社 · 03-12
百利天恒回购70万股 金额2亿元
华夏时报：百利天恒业绩变脸 从年赚37亿到年亏10.5亿
中金财经 · 03-12
华夏时报：百利天恒业绩变脸 从年赚37亿到年亏10.5亿
聚焦四川上市公司 | 42家上市川企发布2025年业绩预告智明达预增4倍领跑，百利天恒由盈转亏
金融投资网 · 03-09
聚焦四川上市公司 | 42家上市川企发布2025年业绩预告智明达预增4倍领跑，百利天恒由盈转亏
一年净赚37亿元到巨亏10亿元！百利天恒业绩“变脸”，创新药烧钱模式能撑多久？
华夏时报网 · 03-09
一年净赚37亿元到巨亏10亿元！百利天恒业绩“变脸”，创新药烧钱模式能撑多久？
百利天恒（688506）披露注射用BL-M11D1获临床试验批准通知书，3月5日股价上涨4.84%
证券之星 · 03-05
百利天恒（688506）披露注射用BL-M11D1获临床试验批准通知书，3月5日股价上涨4.84%
百利天恒：自研ADC药物注射用BL-M11D1获批临床
财中社 · 03-04
百利天恒：自研ADC药物注射用BL-M11D1获批临床
百利天恒累计回购54万股 金额1.61亿元
财中社 · 03-03
百利天恒累计回购54万股 金额1.61亿元
百利天恒：2025年归母净亏损10.51亿元 同比盈转亏
每日经济新闻 · 02-27
百利天恒：2025年归母净亏损10.51亿元 同比盈转亏
首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓
金融投资报 · 02-27
首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓
百利天恒双抗ADC达到Ⅲ期临床试验主要终点 为三阴性乳腺癌治疗提供新选项
每日经济新闻 · 02-24
百利天恒双抗ADC达到Ⅲ期临床试验主要终点 为三阴性乳腺癌治疗提供新选项
百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点
智通财经 · 02-23
百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":286.78,"timestamp":1774594800000,"preClose":255,"halted":0,"volume":3445028,"delay":0,"changeRate":0.1246,"floatShares":413000000,"shares":413000000,"eps":-2.0646,"marketStatus":"已收盘","change":31.78,"latestTime":"03-27 15:00:00","open":253.99,"high":288.93,"low":253,"amount":953000000,"amplitude":0.1409,"askPrice":286.79,"askSize":7,"bidPrice":286.78,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-2.0646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":5,"adr":0,"adjPreClose":255,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774575000000,1774582200000],[1774587600000,1774594800000]],"highLimit":280.5,"lowLimit":229.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":16.51,"roa":"--","roe":"--","epsLYR":9.25,"committee":-0.512821,"marketValue":118404000000,"turnoverRate":0.0083,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-03-30。","afterMarket":{"amount":0,"volume":0,"close":286.78,"buyVolume":0,"sellVolume":0,"time":1774596837558,"indexStatus":"已收盘 03-27 15:30:00","preClose":255},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1774598400000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":118404000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2622866571","title":"百利天恒（688506）披露归还临时补充流动资金的募集资金公告，3月26日股价下跌3.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622866571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622866571?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:12","pubTimestamp":1774534343,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，百利天恒报收于255.0元，较前一交易日下跌3.09%，最新总市值为1052.83亿元。该股当日开盘263.37元，最高270.5元，最低253.69元，成交额达3.56亿元，换手率为0.33%。近日，四川百利天恒药业股份有限公司发布《关于归还临时补充流动资金的募集资金的公告》。截至2026年3月26日，公司已将上述6,000万元全部归还至募集资金专用账户，使用期限未超期，并已通知保荐机构和保荐代表人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600044081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","BK0239","688506"],"gpt_icon":0},{"id":"2622901238","title":"百利天恒（688506）1187.38万股限售股将于3月25日解禁，占总股本2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622901238","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622901238?lang=zh_cn&edition=full","pubTime":"2026-03-25 08:15","pubTimestamp":1774397757,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，百利天恒于3月25日将有1187.38万股限售股份解禁，为公司定向增发机构配售股份，占公司总股本2.88%。最近一年内，该股累计解禁3.09亿股，占总股本的74.82%。百利天恒主营业务：药品的研发、生产与营销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500010489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","91194","02615"],"gpt_icon":0},{"id":"2621977497","title":"百利天恒（688506）披露BL-ARC002获晚期实体瘤临床试验批准通知书，3月23日股价下跌4.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621977497","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621977497?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:56","pubTimestamp":1774259767,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，百利天恒报收于258.2元，较前一交易日下跌4.89%，最新总市值为1066.04亿元。该股当日开盘265.0元，最高268.0元，最低254.9元，成交额达3.39亿元，换手率为0.32%。四川百利天恒药业股份有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司自主研发的创新药BL-ARC002注射液开展晚期实体瘤的临床试验。药品从研发到上市存在周期长、环节多、高风险等特点，需完成临床试验并经审评审批后方可上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300028289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","BK0239","91194"],"gpt_icon":0},{"id":"2621371933","title":"百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621371933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621371933?lang=zh_cn&edition=full","pubTime":"2026-03-22 15:41","pubTimestamp":1774165288,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新药BL-ARC002注射液的药物临床试验获得批准。公告称，BL-ARC002通过抗体介导的精准靶向递送技术及放射性核素强大的肿瘤杀伤能力，与传统放射性核素偶联药物相比，具有更强的靶点特异性、更高的肿瘤富集性，并有望展现出更好的抗耐药性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","91194","06978","688506","BK0239","BK4023","02615","159992","LU1815336091.USD","BL","LU0757428866.USD","BK1161"],"gpt_icon":0},{"id":"2621795056","title":"每周股票复盘：百利天恒（688506）2.88%限售股将上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2621795056","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621795056?lang=zh_cn&edition=full","pubTime":"2026-03-22 01:29","pubTimestamp":1774114150,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，百利天恒报收于271.48元，较上周的257.33元上涨5.5%。本周关注点公司公告汇总：百利天恒2.88%限售股将于2026年3月25日上市流通公司公告汇总：本次限售股涉及中欧基金、易方达基金等18名机构投资者公司公告汇总：限售股锁定期6个月，保荐机构中信证券无异议公司公告汇总百利天恒向特定对象发行的11,873,817股限售股将于2026年3月25日上市流通，占公司总股本的2.88%。中信证券作为保荐人，对本次限售股上市流通无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","02615","688506"],"gpt_icon":0},{"id":"2620624216","title":"百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2620624216","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620624216?lang=zh_cn&edition=full","pubTime":"2026-03-19 13:35","pubTimestamp":1773898522,"startTime":"0","endTime":"0","summary":"百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677222420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","02615","91194"],"gpt_icon":0},{"id":"1105344324","title":"百利天恒：1190万股限售股解禁 3月25日起上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=1105344324","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105344324?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:35","pubTimestamp":1773743711,"startTime":"0","endTime":"0","summary":"百利天恒宣布，公司约1190万股限售股份即将解除限售条件，并将于3月25日正式进入二级市场流通交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2620428282","title":"百利天恒：1187.38万股限售股3月25日解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428282","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620428282?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:50","pubTimestamp":1773741038,"startTime":"0","endTime":"0","summary":"南财智讯3月17日电，百利天恒公告，公司向特定对象发行的限售股将于2026年3月25日上市流通，本次解禁股份数量为1187.38万股，占公司总股本的2.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603173674678418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","02615","688506","91194"],"gpt_icon":0},{"id":"2619178242","title":"每周股票复盘：百利天恒（688506）完成1.99亿元股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2619178242","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619178242?lang=zh_cn&edition=full","pubTime":"2026-03-15 03:09","pubTimestamp":1773515351,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，百利天恒报收于257.33元，较上周的258.5元下跌0.45%。本周，百利天恒3月10日盘中最高价报285.0元。本周关注点公司公告汇总：百利天恒已完成约2亿元股份回购，累计回购695,862股。公司公告汇总四川百利天恒药业股份有限公司于2025年12月30日召开董事会，审议通过回购股份方案，拟以集中竞价交易方式回购公司股份，用于员工持股计划或股权激励。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","BK0239","91194"],"gpt_icon":0},{"id":"2618139911","title":"百利天恒回购70万股 金额2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618139911","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618139911?lang=zh_cn&edition=full","pubTime":"2026-03-12 19:25","pubTimestamp":1773314707,"startTime":"0","endTime":"0","summary":"百利天恒（688506）发布公告，截至2026年3月12日，公司已回购70万股，占总股本的0.17%，实际回购金额为2亿元，回购价格区间为243.44元/股至345.24元/股。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603123670321391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"2618188071","title":"华夏时报：百利天恒业绩变脸 从年赚37亿到年亏10.5亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2618188071","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618188071?lang=zh_cn&edition=full","pubTime":"2026-03-12 14:42","pubTimestamp":1773297724,"startTime":"0","endTime":"0","summary":"中国经济网北京3月12日讯 华夏时报9日报道《一年净赚37亿元到巨亏10亿元！百利天恒业绩“变脸”，创新药烧钱模式能撑多久？》显示，百利天恒 于2026年2月28日发布2025年年度业绩快报公告。公告显示，公司在2025年实现营业总收入25.2亿元，较上年同期的58.23亿元减少56.72%；归属于母公司所有者的净利润为-10.51亿元，较上年同期的37.08亿元大幅转亏，同比减少128.34%。2025年仅前三季度，百利天恒研发费用就高达17.72亿元，同比增长90.23%。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/12/20260312157276.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/12/20260312157276.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260312/32062948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02615","91194","BK0239","688506"],"gpt_icon":0},{"id":"2618646015","title":"聚焦四川上市公司 | 42家上市川企发布2025年业绩预告智明达预增4倍领跑，百利天恒由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646015","media":"金融投资网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618646015?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:36","pubTimestamp":1773045375,"startTime":"0","endTime":"0","summary":"A股上市公司2025年业绩快报还在持续披露中，截至目前，四川省内已有42家上市公司发布了2025年业绩快报。就已发布业绩快报的四川上市公司的情况来看，其业绩呈现喜忧参半的态势。Wind统计数据显示，在已披露业绩快报的四川上市公司中，有21家全年业绩实现同比增长，占披露总数的一半，其余21家的业绩则出现了不同程度的下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666101871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0214","91194","688506","BK0239","02615","688636"],"gpt_icon":0},{"id":"2618646523","title":"一年净赚37亿元到巨亏10亿元！百利天恒业绩“变脸”，创新药烧钱模式能撑多久？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646523","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618646523?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:23","pubTimestamp":1773044603,"startTime":"0","endTime":"0","summary":"四川百利天恒药业股份有限公司（下称“百利天恒”，股票代码：688506.SH）于2026年2月28日发布2025年年度业绩快报公告。公告显示，公司在2025年实现营业总收入25.2亿元，较上年同期的58.23亿元减少56.72%；归属于母公司所有者的净利润为-10.51亿元，较上年同期的37.08亿元大幅转亏，同比减少128.34%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603093666088735.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666088735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","688506","BK0239","BK1161","BK1574","91194","159992","06978"],"gpt_icon":0},{"id":"2617517185","title":"百利天恒（688506）披露注射用BL-M11D1获临床试验批准通知书，3月5日股价上涨4.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517185","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617517185?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:20","pubTimestamp":1772702439,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，百利天恒报收于254.87元，较前一交易日上涨4.84%，最新总市值为1052.29亿元。四川百利天恒药业股份有限公司于2026年3月5日发布自愿披露公告，称公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司自主研发的创新生物药注射用BL-M11D1开展用于治疗复发或难治性骨髓增生异常综合征的临床试验。目前BL-M11D1在国内进行Ib期临床试验，在美国进行I期临床试验，适应症为复发或难治性急性髓系白血病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500027855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"2616318725","title":"百利天恒：自研ADC药物注射用BL-M11D1获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2616318725","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616318725?lang=zh_cn&edition=full","pubTime":"2026-03-04 18:46","pubTimestamp":1772621169,"startTime":"0","endTime":"0","summary":"3月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M11D1（CD33-ADC）的药物临床试验获得批准。BL-M11D1是与iza-bren出自同一技术平台、与iza-bren共享同一“连接子+毒素”平台的靶向CD33的ADC药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603043661878918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK0239","688506","BK4023","LU1815336091.USD","BK4080","BL","02615","LU0757428866.USD","ADC","BK4231"],"gpt_icon":0},{"id":"2616834626","title":"百利天恒累计回购54万股 金额1.61亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616834626","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616834626?lang=zh_cn&edition=full","pubTime":"2026-03-03 18:32","pubTimestamp":1772533937,"startTime":"0","endTime":"0","summary":"3月3日，百利天恒（688506）发布公告，截至2026年2月28日，公司累计回购54万股，占总股本的0.13%，回购资金总额为1.61亿元，实际回购价格区间为267.36元/股至345.24元/股。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660497540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","91194","BK0239","688506"],"gpt_icon":0},{"id":"2614799835","title":"百利天恒：2025年归母净亏损10.51亿元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614799835","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614799835?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:19","pubTimestamp":1772183985,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月27日，百利天恒(688506.SH)发布2025年年度业绩快报，营业总收入为25.20亿元，同比减少56.72%；归属于母公司所有者的净利润为-10.51亿元，同比盈转亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656760446.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656760446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","91194","02615"],"gpt_icon":0},{"id":"2614083875","title":"首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083875","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614083875?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:51","pubTimestamp":1772182279,"startTime":"0","endTime":"0","summary":"金融投资报记者贺梦璐“盈利了，但市值却跌破3000亿元。”这或许是百济神州发布2025年度业绩快报后，留给资本市场的最大困惑。金融投资报记者注意到，当投资者将目光转向其股东名单时，一个有意思的巧合开始浮现：那些重仓百济神州的公募基金，同样也对川股百利天恒青睐有加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656715059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","BK4588","BK1583","06160","BK4526","688506","LU2328871848.SGD","BK1588","ONC","BK1500","LU0307460666.USD","91194","BK4139","LU1719994722.HKD","02615","688235","LU1770034418.SGD","LU1969619763.USD","BK0239","BK4585","LU1251922891.USD","BK1161","LU1303224171.USD"],"gpt_icon":0},{"id":"2613713953","title":"百利天恒双抗ADC达到Ⅲ期临床试验主要终点 为三阴性乳腺癌治疗提供新选项","url":"https://stock-news.laohu8.com/highlight/detail?id=2613713953","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613713953?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:39","pubTimestamp":1771933190,"startTime":"0","endTime":"0","summary":"2月23日，百利天恒（SH688506，股价289.59元，市值1195.6亿元）宣布其自主研发的全球首创EGFR×HER3双抗ADC药物（抗体偶联药物）iza-bren，在针对局部晚期或转移性三阴性乳腺癌（TNBC）的Ⅲ期临床试验中取得突破。期中分析数据显示，该药物显著延长了患者的无进展生存期（PFS）和总生存期（OS），达到双主要终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652920641.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652920641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","BK4080","BK4231","ADC","02615","91194"],"gpt_icon":0},{"id":"2613820071","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2613820071","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613820071?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:56","pubTimestamp":1771836964,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 披露公告，关于iza-bren用于局部晚期或转移性三阴乳腺癌III期临床试验的期中分析达到主要终点的事项，该III期临床研究独立数据监查委员会，在预设的期中分析中，建议：“基于现有的分析结果，与监管沟通提前申报，同时继续对受试者进行随访”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688506","ADC","91194","III","BK4231","02615","BK0239","BK4080","BK4134"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774648307941,"stockEarnings":[{"period":"1week","weight":0.0564},{"period":"1month","weight":0.0275},{"period":"3month","weight":-0.1529},{"period":"6month","weight":-0.2309},{"period":"1year","weight":0.2753},{"period":"ytd","weight":-0.1124}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0563},{"period":"3month","weight":-0.0126},{"period":"6month","weight":0.0224},{"period":"1year","weight":0.1601},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5979人(较上一季度增加25.08%)","perCapita":"69053股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}